- Home
- Publications
- Publication Search
- Publication Details
Title
Fool’s gold, lost treasures, and the randomized clinical trial
Authors
Keywords
Randomized clinical trials, Gold standard, Phase II trials, Drug combinations, Biomarkers
Journal
BMC CANCER
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2013-04-16
DOI
10.1186/1471-2407-13-193
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Why RECIST Works and Why It Should Stay--Counterpoint
- (2012) A. T. Fojo et al. CANCER RESEARCH
- Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819
- (2012) M. W. Redman et al. CLINICAL CANCER RESEARCH
- Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure
- (2012) G. D. Demetri et al. CLINICAL CANCER RESEARCH
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
- (2012) Peter Mulders et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma
- (2012) M. Nagane et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Before We Throw out Progression-Free Survival As a Valid End Point…
- (2012) David J. Stewart JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
- (2012) Jin Soo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of Chemotherapy onEGFRMutation Status Among Patients With Non–Small-Cell Lung Cancer
- (2012) Hua Bai et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
- (2012) Chiun Hsu et al. JOURNAL OF HEPATOLOGY
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Response to Erlotinib in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component
- (2012) P. K. Paik et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study
- (2012) J. Sastre et al. ONCOLOGIST
- Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
- (2012) Sai-Hong Ignatius Ou et al. ONCOLOGIST
- A two-stage Bayesian design for co-development of new drugs and companion diagnostics
- (2012) Stella Wanjugu Karuri et al. STATISTICS IN MEDICINE
- Clinical trials for predictive medicine
- (2012) Richard Simon STATISTICS IN MEDICINE
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53
- (2011) Michelle Martinez-Rivera et al. BIOCHEMICAL PHARMACOLOGY
- Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
- (2011) J M del Campo et al. BRITISH JOURNAL OF CANCER
- Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene
- (2011) N. A. Rizvi et al. CLINICAL CANCER RESEARCH
- Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics
- (2011) H. I. Scher et al. CLINICAL CANCER RESEARCH
- Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung
- (2011) R. Takahashi et al. CLINICAL CANCER RESEARCH
- Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
- (2011) J. E. Chaft et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non–Small-Cell Lung Cancer
- (2011) Athanasios G. Pallis et al. Clinical Lung Cancer
- Genomic biomarkers in predictive medicine. An interim analysis
- (2011) Richard Simon EMBO Molecular Medicine
- Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
- (2011) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
- (2011) Wolfram Brugger et al. JOURNAL OF CLINICAL ONCOLOGY
- Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes
- (2011) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
- (2011) Jean-Pascal Machiels et al. LANCET ONCOLOGY
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell’Italia Meridionale Multicenter Phase II Study
- (2011) Giuseppe Colucci et al. ONCOLOGY
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
- (2010) Gabriel N. Hortobagyi et al. BREAST CANCER RESEARCH AND TREATMENT
- Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development
- (2010) Tatiana Vidaurre et al. CANCER JOURNAL
- The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
- (2010) L. Seymour et al. CLINICAL CANCER RESEARCH
- Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review
- (2010) Jolien Tol et al. CLINICAL THERAPEUTICS
- Bayesian adaptive randomization designs for targeted agent development
- (2010) J. Jack Lee et al. Clinical Trials
- Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer
- (2010) David J. Stewart CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies
- (2010) Sarah Barton et al. CURRENT CANCER DRUG TARGETS
- Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study
- (2010) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trials: Misleading and Unreliable
- (2010) David J. Stewart JOURNAL OF CLINICAL ONCOLOGY
- Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research
- (2010) David J. Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Clinical Trials With Biomarkers: Design Issues
- (2010) B. Freidlin et al. JNCI-Journal of the National Cancer Institute
- When Are "Positive" Clinical Trials in Oncology Truly Positive?
- (2010) A. Ocana et al. JNCI-Journal of the National Cancer Institute
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease
- (2010) Gregg W. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
- (2010) Jennifer S. Temel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
- (2009) D. M. Jackman et al. CLINICAL CANCER RESEARCH
- Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study
- (2009) Jean-Claude Barbare et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer
- (2009) Humberto Lara-Guerra et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status
- (2009) Glenwood Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- (2009) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trials inJournal of Clinical Oncology
- (2009) Stephen A. Cannistra JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial
- (2009) Apostolia-Maria Tsimberidou et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
- (2009) Guido Sauter et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
- (2009) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
- (2009) Alison T. Stopeck et al. LEUKEMIA & LYMPHOMA
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
- The Use of Genomics in Clinical Trial Design
- (2008) R. Simon CLINICAL CANCER RESEARCH
- Randomized Phase III Clinical Trial Designs for Targeted Agents
- (2008) A. Hoering et al. CLINICAL CANCER RESEARCH
- Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
- (2008) Robert H. El-Maraghi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma
- (2008) Jacek Jassem et al. JOURNAL OF CLINICAL ONCOLOGY
- Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
- (2008) Chang-Qi Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment
- (2008) Kathy S. Albain et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741
- (2008) Hanna K. Sanoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer: The Road to Amiens
- (2008) David J. Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
- (2008) Kenneth Jamerson et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started